

AliveCor expands into Chinese Heart Health Market

29 April 2019 | News | By Kalyani Sharma

It is recommended by cardiologists and used by people worldwide for accurate ECG recordings



AliveCor, the leader in FDA-cleared mobile electrocardiogram (ECG) technology has announced an agreement with Beijing Dream Tree Medical Technology Co. Ltd., a leading innovative healthcare service provider in China.

Studies reveal that nearly 300 million Chinese suffer from heart disease, with 13 million at risk of stroke and 10 million currently living with atrial fibrillation (AFib). Supply of AliveCor's FDA-cleared, mobile ECG technology will be critical as physicians look to deliver a higher standard of reliable and cost-effective care to patients suffering from this disease within China.

Ira Bahr, Chief Executive, AliveCor said, "The creation of a powerful partnership allowing AliveCor to access the Chinese market is an enormous step for the company, and an enormous step for hundreds of millions of aging Chinese who can now have ready access to our products."

Dream Tree CEO Wang Jian said, "Heart disease is a leading cause of death in China. AliveCor's affordable, pocket-sized ECG technology is capable of detecting AFib with clinical-grade accuracy and allows us to continue to meet the changing market demands of healthcare. We believe the combination of Dream Tree's solution and AliveCor's personal ECG platform will help Dream Tree empower patients with state of the art heart health technology."

The FDA-cleared KardiaMobile is clinically validated mobile ECG solution on the market. It is recommended by cardiologists and used by people worldwide for accurate ECG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an ECG.